What is CellCentric?
Founded in 2003, CellCentric operates at the forefront of the life sciences sector, specializing in the discovery and advancement of innovative drug candidates. By focusing on specific cancer pathways, the company has transitioned from early-stage research to a clinical-stage entity, leveraging deep scientific expertise to navigate the complexities of pharmaceutical development. Its market position is bolstered by a strategic approach to drug discovery, which prioritizes high-impact therapeutic outcomes and sustainable innovation within the global oncology landscape.
How much funding has CellCentric raised?
CellCentric has raised a total of $424M across 5 funding rounds:
Unspecified
$26M
Unspecified
$33M
Other Financing Round
$25M
Series C
$120M
Series D
$220M
Unspecified (2018): $26M with participation from Morningside Venture Partners
Unspecified (2020): $33M led by Morningside Venture Investments
Other Financing Round (2023): $25M supported by Pfizer
Series C (2025): $120M featuring BrightEdge, Avego Healthcare Capital, Forbion, and RA Capital Management
Series D (2026): $220M backed by Fidelity, BrightEdge - American Cancer Society, HBM Partners, Avego, Sofinnova Partners, Pfizer, Venrock, RA Capital Management, and Forbion
Key Investors in CellCentric
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools.
Forbion
Forbion is a global life sciences venture capital firm that sources, builds, and guides biotech and biopharmaceutical companies from early stage through clinical development.
Pfizer
Pfizer Inc. is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering innovative medicines and vaccines that improve health outcomes.
What's next for CellCentric?
With the successful closure of this latest financing, CellCentric is well-positioned to accelerate its clinical development programs. The influx of capital will likely be deployed to advance its lead candidates through critical trial phases, enhancing the company's ability to bring transformative medicines to market. As the firm continues to scale, it will focus on strengthening its research infrastructure and expanding its collaborative efforts with global healthcare partners to ensure the successful translation of its scientific discoveries into viable patient solutions.
See full CellCentric company page
